SCOR announces the launch of a cash tender offer and its intention to issue new subordinated notes

SCOR SE announced it is launching a cash tender offer to buy EUR 250m 5 June 2047 subordinated notes (EUR 250m outstanding) and EUR 500m 27 May 2048 subordinated notes (EUR 500m outstanding). The offer runs 27 May–3 June 2026 and is conditional on issuing new Tier 2-eligible subordinated notes; proceeds will fund the tender.

Original reporting
Published May 27, 2026, 7:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 8:12 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SCOR announces the launch of a cash tender offer and its intention to issue new subordinated notes — source image
Decision brief

The 30-second read

$SCORNeutralMed
01

Why it matters

The transaction is designed to fund the tender offer using net proceeds from the new subordinated notes, with acceptance priority for 2047 notes and potential allocation mechanics for participating holders.

02

Market read

This is a capital-structure refinancing event with a defined tender window and conditional issuance, likely impacting SCOR’s subordinated debt pricing and related equity/credit sentiment.

03

What to watch

Tender is conditional on successful issuance; any delay/failed syndication could extend uncertainty and widen subordinated spreads until execution clarity.

Relevance 8/10Timing: High: tender offer runs 27 May 2026 to 3 June 2026 (Paris time), with results expected shortly after expiration.

Background

SCOR is a global reinsurer and the company is managing its financing structure by refinancing fixed-to-reset subordinated debt with new Euro fixed-to-floating Tier 2-eligible notes under Solvency II.

Company-level read

Ticker impact

$SCORNeutralMedium confidence
Context

SCOR launched a EUR cash tender offer for its 2047/2048 fixed-to-reset subordinated notes and plans to issue new Tier 2-eligible subordinated notes to fund it.

Expected impact

Near-term: modest volatility in SCOR credit and equity as investors price refinancing execution risk and potential changes in capital metrics; direction depends on tender economics and new-note terms.

Evidence & confidence

The article provides clear financing actions (tender + new subordinated notes) and states proceeds fund the tender, but it does not disclose coupon/yield, acceptance levels, or regulatory capital impact beyond Tier 2 eligibility.

Market effects

Reinsurers’ Tier 2 capital management (Solvency II eligibility) can influence sector credit sentiment and relative value in subordinated issuance/refinancing.

Primarily European credit markets (Luxembourg-listed notes; Paris time schedule) with potential spillover to European insurers/reinsurers’ subordinated curves.

Limited direct global catalyst, but it can affect global reinsurance credit indices via changes in outstanding subordinated supply/demand.

Counterpoint

If the new notes’ pricing is unattractive or acceptance is low, the refinancing could be viewed as a capital-constraint signal rather than proactive optimization.

Key entities

  • SCOR SE

    Announced a cash tender offer for its 2047 and 2048 fixed-to-reset subordinated notes and intends to issue new Tier 2-eligible subordinated notes to finance it.

Related articles

$SCORMed

Why is SCOR stock rallying today? By Investing.com

SCOR SE shares rose about 3.5% to 34.58 on Euronext Paris after the company reported Q2 2026 results. SCOR posted net income of EUR 171 million in Q2 and EUR 397 million for the first half, with a property and casualty combined ratio of 79.5%. Morgan Stanley named SCOR a preferred European insurance pick, citing potential capital release from Solvency II changes in Jan 2027.

$SCORMed

SCOR reports 24% drop in second quarter net income By Investing.com

SCOR SE reported Q2 net income of EUR 171 million, down 24% year over year, with insurance revenue down 5.1%. The property and casualty combined ratio improved to 79.5% on lower catastrophe losses and better attritional performance. Life and health service result was hurt by a one-off arbitration outcome. SCOR posted EUR 397 million net income in H1 2026 and expects continued competitive P&C reinsurance conditions.

$SCORMedAI 9/10

SCOR successfully places EUR 500 million subordinated notes maturing in 2056

SCOR SE said it has placed EUR 500 million fixed-to-floating rate subordinated notes maturing 5 June 2056, eligible as Solvency II Tier 2 capital. The notes pay 4.510% annually until 5 June 2036, then 3-month EURIBOR plus a margin quarterly, with possible interest deferral. Moody’s rates them A3. Proceeds will fund general purposes and a concurrent EUR 250 million tender for 2047 notes; settlement expected 5 June 2026.

$SCORMedAI 9/10

SCOR announces the launch of a cash tender offer and its intention to issue new subordinated notes

SCOR SE said it launched a cash tender offer to buy EUR 250m Fixed to Reset Subordinated Notes due 2047 (ISIN FR0012770063; EUR 250m outstanding) and EUR 500m Fixed to Reset Subordinated Notes due 2048 (ISIN FR0013179314; EUR 500m outstanding). The offer runs 27 May–3 June 2026. SCOR also intends to issue new Tier 2-eligible subordinated notes, with proceeds funding the tender, subject to market conditions.

$MDTMed

Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.